Three studies centred on low-dose digoxin heart failure treatment, led by cardiologists at Universitair Medisch Centrum Groningen (UMCG), now claim the drug reduces hospital admissions for heart failure by an average of 25%, and the evidence base behind that figure is considerably larger than the individual trial alone.
What the UMCG research actually showed
The centrepiece trial enrolled 1,000 people with heart failure treated across 43 centres in the Netherlands. Half received a low dose of digoxin on top of their usual treatment for an average of three years; the other half received a placebo. Among those taking digoxin, deaths from cardiovascular disease and worsening heart failure fell by 19%, though that result on its own did not reach statistical significance.
The researchers then combined those data with results from two earlier studies in a meta-analysis. That pooled analysis, covering the DIG, DIGIT-HF, and DECISION trials and involving more than 9,000 patients, is where the headline numbers come from. According to Medicine Today, the meta-analysis covered all three of those large trials in patients with heart failure with reduced or mildly reduced ejection fraction. Across 9,013 patients, the European Society of Cardiology reports that digitalis glycoside treatment reduced the risk of the primary endpoint (time to cardiovascular death or first worsening heart failure event) compared with placebo, with a hazard ratio of 0.85 (95% CI 0.80 to 0.90; p<0.001). The clearest finding from the combined data was a 25% reduction in hospital admissions for heart failure.
The researchers say low-dose digoxin was also found to be safe and relatively easy to use in this context. The findings were published in Nature Medicine and the Journal of the American Medical Association, and were presented at the ESC Heart Failure Congress in Barcelona.
Low-dose digoxin heart failure evidence and the withdrawal signal
A third study added a different angle. Researchers followed approximately 600 of the original 1,000 participants who had been assigned either digoxin or placebo. Among those who had been taking digoxin and then stopped, problems were substantially more common during the first six weeks than among those who had never taken the drug. Among 288 patients in that group, 14 were hospitalised or died. The UMCG researchers are careful to note that this finding does not directly prove digoxin is effective, but they described the size and timing of the effect as both impressive and surprising.
Heart failure is a condition affecting more than 500,000 people in the Netherlands alone, a number expected to grow. The heart’s inability to pump blood effectively produces severe breathlessness, fatigue, and repeated hospitalisations. Standard care currently relies on a combination of four medications, sometimes referred to as the ‘Fantastic Four.’ Cardiologists have long asked whether digoxin could serve as a fifth treatment alongside them, and the UMCG researchers believe the new data could eventually influence treatment guidelines.
Digoxin’s pharmacology matters here. At low doses, the drug works primarily by suppressing harmful compensatory responses (including stress hormones such as adrenaline) that occur when the heart is struggling. Higher doses, which were common in the past, caused heart muscle cells to contract more forcefully, an effect that ultimately proved less helpful. Reducing strain on a weakened heart turns out to be preferable to forcing it to work harder.
Digoxin use has declined steadily over the past 25 to 30 years as newer treatments arrived, and only about 15% of heart failure patients currently receive it. Earlier research had suggested that patients given low doses did considerably better than those on higher doses, but until this UMCG work, randomised prospective studies had not directly confirmed that specific effect.
The cost dimension is hard to ignore. Digoxin has been used in medicine for centuries and costs less than ten cents per day, against several euros per day for many newer heart failure medications. Research into older, inexpensive drugs can struggle to attract funding precisely because the commercial incentive is absent. Hartstichting provided €3 million for this research through its collaboration with ZonMw as part of the Good Use of Medicines programme.
The UMCG researchers say the results of all three studies could eventually lead to changes in heart failure guidelines, potentially making digoxin available to many more patients. Whether guideline bodies find the evidence sufficient is a separate question, but with a 9,013-patient meta-analysis and a p-value well below conventional thresholds, the case being presented to them is now substantially stronger than it was.
